University of Rochester

Cedars-sinai Medical Center

Edward M Schwarz

John L Daiss

Mark A Sullivan

Christopher T Ritchlin

John J Varrone

James Brodell

Sheila Bello-Irizarry

Kofi A Mensah

Yahui Grace Chiu

Hyun W Bae

Thomas Foster

Dan Gazit

Gadi Pelled

Zulma Gazit

Dmitriy Sheyn

Hani Awad

Brendan F Boyce

Regis James O'Keefe

Lianping Xing

Sally A Haas-Smith

Jarod C Finlay

Wafa Tawackoli

Paul T Rubery

Sheila N Bello-Irizarry

Sally Haas-Smith

Described herein are methods and compositions using PTH and mesenchymal stem cells (MSCs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both PTH and MSCs leads to increased homing of MSCs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and repair. The potential for enhanced bone formation and fracture repair may allow for both preventative and palliative treatments in osteoporotic patients, with combined PTH+MSC therapy producing bone regeneration capacity that is significantly superior to either treatment alone.

Method for non surgical repair of vertebral compression fractures

The present invention is directed to a monoclonal antibody that binds specifically to aglucosaminidase and inhibits in vivo growth of. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treatinginfection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.

Anti-glucosaminidase passive immunization forinfections

Disclosed herein are monoclonal antibodies or binding portion thereof that bind specifically to aspp. autolysin N-acetylmuramoyl-L-alanine amidase catalytic domain and/or cell wall binding domain, as well as pharmaceutical compositions containing the same. Cell lines expressing the monoclonal antibodies, including hybridomas, are also disclosed. Methods of using the monoclonal antibodies for installation of orthopedic implants, grafts or medical devices, treating or preventing ainfection, and treating osteomyelitis are described, as are diagnostic methods for the detection ofin a sample.

Passive immunization forinfections

[object Object]

Provided herein are antibodies that specifically bind an epitope of DC-STAMP. Specifically, provided herein are monoclonal antibodies that bind an epitope of DC-STAMP, wherein the epitope comprises the amino acid sequence Glu-Val-His-Leu-Lys-Leu-His-Gly-Glu-Lys-Gln-Gly-Thr-Gln (SEQ ID NO:1). Optionally, the epitope comprises the amino acid sequence His-Gly-Glu-Lys-Gln-Gly-Thr-Gln (SEQ ID NO:2). Optionally, the epitope comprises the amino acid sequence Lys-Gln-Gly-Thr-Gln (SEQ ID NO:3).

DC-STAMP antibodies

The present invention is directed to a monoclonal antibody that binds specifically to aglucosaminidase and inhibits in vivo growth of. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating 5*.infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.

Embodiments of surgical grafts, and methods, for the delivery of therapeutic agents to a target tissue via acellular matrices, are described. In some embodiments, nonviable matrices are successful in preventing or lessening adhesion formation by guiding tissue repair and remodeling, while also providing the target tissue with therapeutic agents that can act as repair and remodeling factors. An exemplary method to modulate flexor tendon healing and provide elimination or reduction of fibrotic adhesions involves loading a freeze-dried flexor digitorum longus allograft with recombinant adeno-associated viral (rAAV) vectors for the targeted and transient expression of growth/differentiation factor 5 (GDF5).

Targeted delivery of therapeutic agents with lyophilized matrices

The present invention is directed to methods of treating an inflammatory condition in a patient. This method includes providing a therapeutic agent that is a vascular endothelial growth factor receptor-3 (VEGFR-3) agonist or a nucleic acid molecule encoding a VEGFR-3 agonist. The present invention is further directed to pharmaceutical compositions and therapeutic systems for treating an inflammatory condition.

Methods and compositions for treating inflammatory conditions

Disclosed are compositions and methods related to joint inflammation diseases. Disclosed is the relationship between osteoclasts and inflammatory joint diseases and osteoclast precursor cells.

Methods and compositions related to joint inflammation diseases

Growing community of inventors

Rochester, NY, United States of America

Edward M Schwarz